Posted by Michael Wonder on 08 Apr 2020
U.S. FDA approves Braftovi (encorafenib) in combination with cetuximab for the treatment of BRAF V600E mutant metastatic colorectal cancer after prior therapy
8 April 2020 - Braftovi plus cetuximab is the first and only FDA approved targeted regimen specifically for adults with previously treated metastatic colorectal cancer with a BRAF V600E mutation.
Pfizer today announced that the U.S. FDA has approved Braftovi (encorafenib) in combination with cetuximab (marketed as Erbitux) for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy.
The approval is based on results from the BEACON CRC trial, the only Phase 3 trial to specifically study patients with previously treated metastatic CRC with a BRAF V600E mutation.
